

## References

- Abu-Shaweesh JM**, Martin RJ. Neonatal apnea: what's new? *Pediatr Pulmonol*. 2008 Oct;43(10):937-44
- Darnall RA**, John Kattwinkel, Candace Nattie, Melinda Robinson. Margin of Safety for Discharge After Apnea in Preterm Infants. *Pediatrics* Nov 1997, 100 (5) 795-801
- Davis PG et al.** (2010). Caffeine for Apnea of Preamaturity Trial. Benefits May Vary in Subgroups. *J Pediatr*;156:382-7
- De Paoli AG**, Davis PG, Lemyre B. Nasal continuous positive airway pressure versus nasal intermittent positive pressure ventilation for preterm neonates: a systematic review and meta-analysis. *Acta Paediatr*. 2003;92(1):70-5.
- Dobson et al.** (2013). Trends in Caffeine Use and Association between clinical outcomes and timing of therapy in VLBW infants. *J Pediatr*;164:992-8
- Eichenwald EC**; Committee on Fetus and Newborn, American Academy of Pediatrics. Apnea of Prematurity. *Pediatrics*. 2016 Jan;137(1).
- Eichenwald EC**, Aina A, Stark AR. Apnea frequently persists beyond term gestation in infants delivered at 24 to 28 weeks. *Pediatrics*. 1997 Sep;100(3 Pt 1):354-9.
- Henderson-Smart DJ**. The effect of gestational age on the incidence and duration of recurrent apnoea in newborn babies. *Aust Paediatr J*. 1981 Dec;17(4):273-6.
- Henderson-Smart DJ**, De Paoli AG. Methylxanthine treatment for apnoea in preterm infants. *Cochrane Database Syst Rev*. 2010 Dec 8;(12):CD000140
- Henderson-Smart DJ**, De Paoli AG. Prophylactic methylxanthine for prevention of apnoea in preterm infants. *Cochrane Database Syst Rev*. 2010 Dec 8;(12):CD000432
- Katheria A et al** (2015). A Pilot Randomized Controlled Trial of Early Versus Routine Caffeine use in Premature infants. *Am J of Perinatology* epub ahead of print.
- Lodha A et al** (2015). Association of Early Caffeine administration and Neonatal outcomes. *JAMA Pediatr*;169(1):33-38
- Lorch SA et al**; Epidemiology of apnea and bradycardia resolution in premature infants. *Pediatrics*. 2011 Aug;128(2):e366-73
- Patel et al** (2013). Early caffeine therapy and clinical outcomes in extremely preterm infants. *J of Peri*; 33, 134-140
- Ramanathan R et al** (2001). Cardiorespiratory events recorded on home monitors: Comparison of healthy infants with those at increased risk for SIDS. *JAMA* 285(17):2199-207

**Schmidt B et al.** (2006). Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. *N Engl J Med.* 354(20):2112-2121

**Schmidt B et al.** (2007). Caffeine for Apnea of Prematurity Trial Group: Long-term effects of caffeine therapy for apnea of prematurity. *N Engl J Med*; 357:1893-1902.

**Schmidt B, et al.** (2012). Caffeine for Apnea of Prematurity (CAP) Trial Investigators: Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. *JAMA*;307:275-282.

**Sreenan C et al.** (2001). High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure. *Pediatrics.* 107(5):1081-3

**Zhao J et al.** (2011). *Apnea from cause to treatment.* Eur J Pediatr. 170:1097-1105

Schmidt B et al. (2006). *Caffeine for Apnea of Prematurity Trial Group: Caffeine therapy for apnea of prematurity.* N Engl J Med;354:2112-2121.

**Zupancic JA et al.** (2003). Cost-effectiveness analysis of pre-discharge monitoring for apnea of prematurity. *Pediatrics.* 111(1): 146-52.